ARTICLE | Company News
Trimeris, ViroLogic deal
November 6, 2000 8:00 AM UTC
VLGC will provide HIV drug resistance testing services for the Phase III program for T-20, an HIV fusion inhibitor developed by TRMS and partner F. Hoffmann-La Roche Ltd. (SWX:ROCZ, Basel, Switzerla...